Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

CACI International Inc announced today that it has acquired Applied Insight, a Northern Virginia-based portfolio company of Acacia Group, in an all-cash transaction. In alignment with CACI's mission ...

SiriusXM today announced plans to release its third quarter 2024 operating and financial results on Thursday, October 31. The company will hold an investor call the same day at 8:00 a.m.

Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced ...

Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

Medline Industries signed the biggest office lease in suburban Chicago this year, weeks after its massive lease expansion in ...

Tagworks Pharmaceuticals BV ("Tagworks"), a precision oncology company using its proprietary Click-to-Release treatment ...

New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...

UCB taps new UK head. Belgium-based global biopharmaceutical company UCB welcomed Nico Reynders as its new general manager ...